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FORUM REVIEW ARTICLE
Systemic Adiponectin Malfunction as a Risk Factor
for Cardiovascular Disease
Wayne Bond Lau,1 Ling Tao,2 Yajing Wang,1 Rong Li,3 and Xin L. Ma1
Abstract
Adiponectin (Ad) is an abundant protein hormone regulatory of numerous metabolic processes. The 30 kDa
protein originates from adipose tissue, with full-length and globular domain circulatory forms. A collagenous
domain within Ad leads to spontaneous self-assemblage into various oligomeric isoforms, including trimers,
hexamers, and high-molecular-weight multimers. Two membrane-spanning receptors for Ad have been iden-
tified, with differing concentration distribution in various body tissues. The major intracellular pathway acti-
vated by Ad includes phosphorylation of AMP-activated protein kinase, which is responsible for many of Ad’s
metabolic regulatory, anti-inflammatory, vascular protective, and anti-ischemic properties. Additionally, several
AMP-activated protein kinase-independent mechanisms responsible for Ad’s anti-inflammatory and anti-
ischemic (resulting in cardioprotective) effects have also been discovered. Since its 1995 discovery, Ad has
garnered considerable attention for its role in diabetic and cardiovascular pathology. Clinical observations have
demonstrated the association of hypoadiponectinemia in patients with obesity, cardiovascular disease, and
insulin resistance. In this review, we elaborate currently known information about Ad malfunction and defi-
ciency pertaining to cardiovascular disease risk (including atherosclerosis, endothelial dysfunction, and cardiac
injury), as well as review evidence supporting Ad resistance as a novel risk factor for cardiovascular injury,
providing insight about the future of Ad research and the protein’s potential therapeutic benefits. Antioxid. Redox
Signal. 15, 1863–1873.
Introduction
Adiponectin (Ad) is a protein hormone responsible forthe modulation of numerous metabolic processes. In this
review,we shall elaborate currently known information about
Ad malfunction or deficiency pertaining to cardiovascular
disease risk, as well as review evidence supporting Ad resis-
tance as a novel risk factor for cardiovascular injury, provid-
ing insight about the future of Ad research and the protein’s
potential therapeutic cardiovascular benefits.
Ad and Ad Receptors
First described in 1995, Ad had such similarity to comple-
ment factor C1q, the protein was termed Acrp30, as it was an
adipocyte complement-related protein of 30 kDa (53). Three
other groups isolated both mouse and human forms of Ad,
and termed the adipocytokine AdipoQ, apM1, and GBP28,
respectively (24, 36, 39). The human Ad gene exists on chro-
mosome 3q26, a region associated with type-2 diabetes mel-
litus and metabolic syndrome susceptibility (52).
Modulatingmetabolic processes such as glucose regulation
and fatty acid catabolism, Ad has a primary sequence 244
amino acids long, and contains a signal sequence (which
targets the protein for extracellular section, and is cleaved in
the mature peptide) and a nonconserved N-terminal domain,
followed by 22 collagen repeats, and a C-terminal globular
domain that has topologic similarities to tumor necrosis
factor alpha (TNFa), despite dissimilar amino acid sequences
(Fig. 1). Full-length Ad (fAd) requires post-translational
modification for biologic activity (e.g., hydroxylation and
glycosylation), and is secreted from adipocytes in three
major size classes—trimers (*90 kDa; the basic unit), low-
molecular-weight (LMW) hexamers (*180 kDa), and high-
molecular-weight (HMW) isoforms consisting of 12-mers to
18-mers (which can exceed 400 kDa) (Fig. 1). Monomeric Ad
not incorporated into trimers is predicted to be thermody-
namically unstable and has not been observed under native
conditions, but a proteolytic cleavage product of full-length
Ad containing purely globular C-terminal domain has been
postulated to exist in vivo. Recently, studies have shown that
leukocyte elastase (secreted by activated monocytes and
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neutrophils) cleave fAd and generate globular Ad (gAd). Both
in vivo studies and biochemical analysis of purified complexes
suggest that the different Ad isoforms do not interconvert
postcirculatory secretion. The contribution of varying isoforms
of Ad to specific physiological processes is still incompletely
understood. However, considerable evidence suggests that the
HMW form is the biologically active form in the liver, and that
the ratio ofHMWformprevalence to total Ad isoforms quantity
(the SA index) correlates to both insulin and Ad sensitivity (48).
Mutations of the Ad gene (Arg112Cys and Ile164Thr) prevent-
ing trimer assemblage cause impaired secretion from the cell,
and are clinically associated with hypoadiponectinemia (63).
Gly84Arg and Gly90Ser mutants can assemble into trimers and
hexamers, but are unable to form HMWmultimers, and result
in clinical diabetes (63), contributing more evidence to isoform
specificity in insulin sensitization.
At its high circulatory concentration (0.5–30mg/ml), Ad
comprises *0.01% of all plasma proteins (53), thereby ex-
ceeding other adipokines 100-fold, andmost hormones 3-fold.
Contrary to expectations given its major production source,
Ad levels are inversely correlated with body fat percentage in
adults (in stark contrast to leptin levels, which are propor-
tional to adipose mass). fAd or gAd decrease free fatty acid
release in the postprandial state. Systemic insulin sensitivity
and plasma Ad levels are positively correlated, and Ad aug-
ments postprandial insulin’s suppression of hepatic glucose
output. Cnop and colleagues report Ad concentrations to be
significantly higher in women than in men (7.4–2.9 vs. 5.4–
2.3 mg/ml, p < 0.0001, 182 total subjects) (11), which has been
attributed to the inhibitory effect of testosterone upon Ad
secretion by epidemiological puberty data (7), and reaffirmed
in hormonal replacement therapy in male to female trans-
gender studies (5, 50). Sexual dimorphism exists regarding
oligomeric distribution, as males harbor a predominance of
LMWAd, whereas females have amore balanced distribution
of both LMW and HMW forms (48).
For many years, Ad was believed to be exclusively secreted
by adipocytes. Although an overwhelming majority of the
body’s Ad is generated from white adipose tissue, it has been
shown that the Ad gene is expressed in other cell types, in-
cluding osteoblasts, skeletal muscle, and cardiomyocytes. Our
recent study has shown that cardiomyocytes-derived Ad is
biologically active and contributes to physiologic function (65).
Ad regulates cellular function via binding and activation of
its specific receptors, Ad receptor 1 (AdipoR1) and Ad re-
ceptor 2 (AdipoR2), each encoded by their respectively named
genes. The Ad receptors belong to a new family of membrane
receptors structurally predicted to contain seven transmem-
brane domains, but are topologically distinct from G-coupled
receptor proteins. Ad binds to the C-terminal extracellular
domain of AdipoR, whereas the N-terminal cytoplasmic do-
main interacts with an adaptor protein, APPL1 (Fig. 2). Adi-
poR1 is abundantly expressed in skeletal muscle and
endothelial cells, and AdipoR2 is predominantly expressed in
the liver (75). Both AdipoR1 and AdipoR2 are constitutively
expressed in adult cardiomyocytes, but studies resolving each
FIG. 1. Structure of Ad (human).
Full-length Ad requires post-trans-
lational modifications (e.g., hy-
droxylation and glycosylation) for
activity. Ad molecules are secreted
from adipocytes as trimers
(*90 kDa; the basic unit), LMW
hexamers (*180 kDa), and HMW
isoforms (12–18-mers; > 400 kDa).
AA, amino acid (length); Ad, adi-
ponectin; C, carboxy-terminus;
HMW, high molecular weight;
LMW, low molecular weight; N,
amino-terminus. (To see this illus-
tration in color the reader is re-
ferred to the web version of this
article at www.liebertonline.com/
ars).
FIG. 2. Ad and the Ad receptor. Ad interacts with the
extracellular C-terminus region of the Ad receptor, which
spans the membrane in seven domains, with its N-terminus
intracellular, interacting with APPL1. T-cadherin is postu-
lated to be a receptor for multimeric HMW Ad isoforms,
with yet unknown biologic function. AdipoR1/R2, Ad re-
ceptor 1/2; APPL1, adapter protein. (To see this illustration
in color the reader is referred to the web version of this article
at www.liebertonline.com/ars).
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receptor’s relative contribution to Ad cardioprotective sig-
naling remain ongoing. Receptor expression levels in skeletal
muscle and adipose tissue correlate with insulin levels, and
are reduced in diabetic mouse models (6, 16). By Scatchard
plot analysis, Yamuchi and colleagues have shown that Adi-
poR1 is a receptor with high affinity for globular Ad, whereas
AdipoR2 is a receptor with intermediate affinity for both full-
length and globular Ad (70, 75).
In addition to the two Ad receptors, T-cadherin has been
proposed to be a receptor for the hexameric and HMW Ad
forms, and has been found to be capable of binding Ad in
C2C12 myoblasts, but not in hepatocytes (25). However, as T-
cadherin lacks an intracellular domain, the specific biologic
function of anyAd/T-cadherin interaction remains unknown.
Calreticulin (CRT), a multifunctional chaperone protein
binding calcium ions, in concert with its adaptor protein
CD91, has been identified by Walsh’s group (40, 60) to be yet
another receptor for Ad. Ad’s interactionwith CRT/CD91 has
been shown to exert endothelial anti-inflammatory and vas-
culoprotective effects. As Walsh’s group has acknowledged,
CRT/CD91 does not constitute a classical receptor pathway,
but, in addition to its overwhelming serum abundance, Ad is
not a typical ligand with its unique property of higher-order
oligimerization (40). The CRT/CD91 receptor pathway is
discussed further in the section AMPK-independent signaling
mechanisms.
Ad Intracellular Signaling
More than a decade of both clinical and experimental in-
vestigation has identified four central biological functions for
Ad: (i) a metabolic regulatory function (via increasing insulin
sensitivity, increasing glucose utilization, and increasing fatty
acid oxidation); (ii) a vascular protective function (by enhanc-
ing nitric oxide [NO] production, and stimulating angiogene-
sis); (iii) an anti-inflammatory role (through decreasing both
neutrophil adhesion and macrophage activation); and (iv) a
cardioprotective/anti-ischemic function (19).
The specific mechanisms underlying these biologic func-
tions of Ad can be separated by their dependency upon the
AMP-activated protein kinase (AMPK) axis. AMPK is the first
and most recognized molecule in Ad intracellular signaling.
Ad regulates cellular metabolism through the AMPK/acetyl-
CoA carboxylase signaling axis (71). Ad inhibits the inflam-
matory response and elicits vasodilatation/vasculoprotection
largely through the AMPK/endothelial NO synthase (eNOS)
axis (10, 55). However, Ad signaling involved with vasculo-
protection, anti-inflammatory response, and cardioprotection
all have been demonstrated to be mediated via AMPK-
independent mechanisms.
AMPK-dependent signaling mechanisms
Figure 3 summarizes the AMPK-dependent metabolic
functions of Ad. The major intracellular pathway activated by
Ad is AMPK, a metabolic switch responsible for regulation of
several intracellular systems, including glucose uptake, glu-
cose transporter 4 generation, fatty acid oxidation, and mi-
tochondrial genesis. The phosphorylative activation of AMPK
by Ad causes resultant phosphorylative inactivation of acetyl
co-A carboxylase, which in turn affects metabolic activity via
various downstream cellular mechanisms. Inactive phos-
phorylated acetyl co-A carboxylase reduces malonyl-coA
formation, which ceases inhibition of carnitine palmitoyl-
transferase 1, which increases fatty acid flux into the mito-
chondria for oxidation (2). AMPK activation additionally
reduces the expression of molecules involved in gluconeo-
genesis, such as phosphoenolpyruvate carboxykinase and
glucose-6-phosphatase in hepatocytes (34). Therefore, via
the AMPK axis, Ad stimulates increased glucose utilization,
FIG. 3. AMP Kinase-
dependent metabolic func-
tions of Ad. Ad interacts with
the extracellular C-terminus
region of the Ad receptor,
which spans the membrane in
seven domains, with its N-
terminus intracellular, and
causes activation of AMP ki-
nase. Of the four identified
central biological functions
for Ad, its metabolic regula-
tory function and vascular
protective function are de-
pendent upon the AMP ki-
nase signaling axis. ACC,
acetyl co-A carboxylase;
AMPK, AMP-activated pro-
tein kinase; CPT1, carnitine
palmotyltransferase 1; G6Pase,
glucose-6-phosphatase; GF,
growth factors; PEPCK, phos-
phoenolpyruvate carboxykinase.
(To see this illustration in color
the reader is referred to the web
version of this article at www
.liebertonline.com/ars).
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increased fatty acid oxidation, increased muscle glucose up-
take, increased myocyte lactate production, decreased liver
gluconeogenesis, and decreased in vivo plasma glucose levels
(71). The abrogration of each of Ad’s metabolic effects by the
blocking of AMPK via a dominant-negative mutation in an
experimental model gives evidence to the integral involve-
ment of AMPK for Ad’s metabolic functions (8, 71, 72).
The anti-inflammatory and vasculoprotective effects of Ad
similarly share activation via the AMPK axis. Considerable
evidence supports Ad as a pro-angiogenic regulator through
AMPK signaling, eliciting angiogenic and antiapoptotic en-
dothelial responses (27, 44). Ad-induced AMPK signaling
promotes phosphatidylinositol 3-kinase-Akt signaling within
muscle, leading to angiogenic growth factor synthesis (59).
Ad also directly stimulates endothelial NO production via
phosphatidylinositol 3-kinase-dependent pathways involv-
ing eNOS phosphorylation at Ser1179 by AMPK, contributing
to its vasodilatory and antiatherogenic properties (10) (please
refer to the section ‘‘Ad and endothelial dysfunction’’). Either
pharmacological inhibition of AMPK activity or genetic sup-
pression of AMPK expression virtually abolishes Ad’s anti-
inflammatory (21), and vasculoprotective (44, 55) effects.
Two ex vivo studies demonstrate the importance of AMPK
to fAd-mediated cardioprotection. Shinmura and colleagues
revealed the value of short-term caloric restriction in elevating
total serum Ad levels, with subsequent AMPK activation and
resultant cardiac protection (58). However, as caloric restric-
tion affects multiple physiologic processes, all positive bene-
fits seen in the study could not be exclusively attributable to
Ad alone. Later, Gonon and colleagues demonstrated fAd’s
protection against myocardial ischemia reperfusion injury via
the AMPK/Akt/NO signaling axis (20). Despite demon-
strating fAd indeed resulted in AMPK phosphorylation in an
isolated heart perfusion model, no determination of resultant
blockade of beneficial fAd effects in the setting of AMPK in-
hibition was made, and no cause–effect relationship was es-
tablished. Although documented to be potent in magnitude,
Ad’s anti-ischemic/cardioprotective effects cannot be strictly
attributed to AMPK mediation solely (15).
AMPK-independent signaling mechanisms
Figure 4 summarizes the AMPK-independent metabolic
functions of Ad. Considerable evidence counters AMPK
phosphorylation as an absolute prerequisite for Ad’s anti-
ischemic/cardioprotective effects. In wild-type as well as
cardiomyocyte-specific AMPK-dominant negative transgenic
mice, Ad significantly reduces ischemia/reperfusion-induced
superoxide/NO overproduction, blocks inducible NOS
(iNOS)/NOX-2 expression, and attenuates protein nitration
(64). Although the precise intracellular molecules mediating
Ad’s AMPK-independent antioxidative/antinitrative action
remain presently undefined, accumulating evidence suggests
that the adenylate cyclase/cAMP/protein kinase-A signaling
axis is involved (19). Moreover, Takemura and colleagues
reported an AMPK-independent mechanism through which
Ad reduces systemic inflammation by promoting early apo-
ptotic cell clearance by macrophages via the CRT/CD91-
dependent pathway (60). Walsh’s group has reported that Ad
exerts cardioprotection partially through AMPK-independent
cyclo-oxygenase 2 (COX-2) activation and subsequent TNFa
inhibition (56). Interestingly, this group recently demon-
strated that Ad activation of COX-2 in endothelial cells is not
mediated by the traditional receptors AdipoR1/2, but rather
by the cell surface CRT/CD91 coreceptor (40). Ad was dem-
onstrated to exert vasculoprotective effects via COX-2-
dependent signaling, enhancing ischemic muscle tissue
revascularization by generation of COX-2-derived prosta-
glandin I2.Via siRNAmanipulation, Walsh’s group identified
that ablation of CRT or its adaptor protein CD91 resulted in
reduced COX-2 induction by Ad, and blocked the PI3-kinase-
Akt signaling pathway.
FIG. 4. AMP Kinase-independent
metabolic and antioxidant functions
of Ad. Recent experimental results
from many investigators, including
our own, demonstrated that several
AMPK-independent pathways exist
that mediate Ad’s anti-inflammatory,
vascular protective, and cardiopro-
tective/anti-ischemic functions. The
interaction of Ad with calreticulin/
CD91 complex has been demon-
strated to lead to both anti-inflamma-
tory and vascular protective effects in
an AMPK-independent manor. A still
un-identified mechanism is responsi-
ble for Ad’s antioxidative/cardiopro-
tective effects (likely via adenylate 29
cyclase/cAMP/PKA). cAMP, cyclic
AMP;COX-2, cyclooxygenase 2; CRT,
calreticulin; iNOS, inducible nitric ox-
ide synthase; NOX2,NADPHoxidase
2/gp91phox; PKA, protein kinase A;
TNFa, tumornecrosis factoralpha. (To
see this illustration in color the reader
is referred to the web version of this
articleatwww.liebertonline.com/ars).
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Shibata and colleagues’ work established varying degrees
of AMPK importance in fAd’s cardioprotective effect in dif-
ferent models (56). While fAd blocks hypoxia/reoxygenation-
induced neonatal cardiomyocyte apoptosis largely through
AMPK activation, Ad’s inhibitory effect on LPS-induced
TNFa production is completely AMPK independent. In vivo
administration of NS398, a cyclooxgenase-2 (COX-2) inhibi-
tor, attenuated the infarct sparing effects of exogenous fAd,
suggesting that COX-2 is also a significant player in fAd’s
cardioprotection s/p myocardial ischemia/reperfusion (MI/
R). Ouedraogo and colleges reported that gAd administration
suppressed glucose-induced superoxide overproduction in
culture endothelial cells, a phenomenon that could not be
abrogated with AMPK inhibitors, suggesting that gAd re-
duced high glucose-induced superoxide overproduction in
AMPK-independent fashion (47). In an in vivo animal study,
we demonstrated that AMPK deficiency enhanced myocar-
dial I/R injury but had minimal effect on Ad’s antioxidant/
antinitrative protection (64). These findingswere confirmed in
our later study utilizing an in vitro model demonstrating
that although Ad’s metabolic and eNOS activation effect is
largely mediated by AMPK, its suppression of superoxide is
not, and this AMPK-independent antioxidant property of
Ad increased nitric oxide bioavailability and exerted signifi-
cant antiapoptotic effect (66). It also provided new evidence
demonstrating that iNOS/NADPH oxidase overexpression
is sufficient to increase nitrative/oxidative stress such that
gAd exerts its AMPK-independent cardioprotection partially
through iNOS/NADPH oxidase suppression.
There is understandable reasoning for the mediation of
Ad’s cardioprotective effects through AMPK-independent
mechanisms. The energy-sensing capability of AMPK origi-
nates from its ability to detect and react to AMP:ATP ratio
fluctuations occurring during muscle stimulation in rest and
exercise. The major substrate of AMPK is AMP, which is
grossly abundant during times of ischemic duress. If Ad is to
have any significant cardioprotective properties, such effects
must be executed through AMPK-independent pathways, as
the dependent pathway would already be AMP-saturated.
Ad’s biological functions are largely determined by the in-
tracellular environment, particularly AMP concentration.
Under pathological conditions in which intracellular AMP
concentrations are not elevated (i.e., muscular insulin resis-
tance and vascular inflammation), AMPK might be the most
important molecule in Ad intracellular signaling. In contrast,
under pathological conditions in which intracellular AMP
concentrations are elevated, and AMPK has already been
significantly activated (such asmyocardial ischemia), Admay
summarily exert its biological actions largely through sig-
naling molecules other than AMPK.
Ad Deficiency as a Risk Factor
of Cardiovascular Disease
Ad and atherosclerosis
It has been increasingly recognized that the diabetic and
obesity state is synonymous with chronic inflammation of
the microcirculation. The resultant deleterious effects of am-
bient TNF and other cytokines, as well as high-glucose levels,
further trigger inflammatory signaling cascades, enhancing
leukocyte–endothelial interactions, leading to elementary
atherosclerotic processes. Ouedraogo’s study investigated the
relationship between decreased Ad levels in obese and type-2
diabetic patients and observed exacerbated microvascular
inflammation; in Ad knockout mice, globular Ad replacement
therapy mitigated the inflamed microvascular endothelium
phenotype (46).
Carotid intima-media thickness, an early marker for ath-
erosclerosis, is inversely related to Ad levels in men (53). Ex-
perimental studies support Ad as an antiatherogenicmolecule
FIG. 5. Ad signaling in endothe-
lial cells. Ad signaling transduction
pathways suppress endothelial cell
activation elicited by high glucose
levels and agonists such as TNF,
and suppresses inflammatory re-
sponses (IKKb and NFkb activa-
tion). Ad enhances NO generation
via AMP kinase cascade activation,
and the cAMP-PKA pathway has
been shown to mediate Ad’s anti-
oxidative and anti-inflammatory
protective effects. CAMs, cell ad-
hesion molecules; eNOS, endothe-
lial nitric oxide synthase; Hsp90,
heat shock protein 90; IKKb, Ikb
kinase; NFkb, nuclear factor kb;
NO, nitric oxide; ROS, reactive ox-
ygen species. (To see this illustra-
tion in color the reader is referred to
the web version of this article at
www.liebertonline.com/ars).
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relevant for the prevention of atherosclerotic plaques. In vitro
studies have demonstrated that Ad is inhibitory upon
monocyte–endothelial adhesion, myeloid differentiation, and
macrophage cytokine production—processes intimately re-
lated with atherosclerotic plaque genesis (41). Ad is directly
inhibitive of atherogenic molecules such as intracellular ad-
hesion molecule-1, vascular cellular adhesionmolecule-1, and
E-selectin (molecules associated with heightened leukocyte
trafficking) (41).
Ad attenuates expression of scavenger receptor class A-1
macrophages and consequent low-density lipoprotein up-
take, diminishing foam cell formation (42). Ad inhibits vari-
ous growth factors in cultured smooth muscle cells, including
platelet-derived growth factor, basic fibroblast growth factor,
heparin-binding epidermal growth factor (EGF)-like growth
factor, and EGF, as well as the cell proliferation andmigration
induced by these elements (1). Additionally, Ad exerts anti-
inflammatory effects on macrophages (73). Most importantly,
increased neointimal formation is observed in Ad knock-out
mice in response to external vascular cuff injury (29). Globular
Ad overexpression results in decreased atherosclerotic lesions
in even mice with proatherogenic apoE -/ - background (1).
Ad and endothelial dysfunction
Endothelial dysfunction, the earliest alteration in vas-
cular pathology, plays a critical role in atherosclerosis de-
velopment. Clinical observations have demonstrated that
hypoadiponectinemia is closely correlated to endothelial
dysfunction in peripheral arteries (30, 35, 45, 57, 61). Our
in vitro studies demonstrated that aortic vascular rings from
Ad knockout mice manifest endothelial dysfunction in terms
of increased superoxide production, decreased eNOS phos-
phorylation, and aberrant vasodilatory response to acetyl-
choline (9). Exogenous globular Ad supplementation to the
Ad -/- mice in vivo attenuated the endothelial dysfunction
measured by these parameters. Morever, we demonstrated
that acute Ad treatment significantly attenuated hyperlipid-
emia-induced endothelial dysfunction in rats via reduction of
oxidative and nitrative stress, by differential regulation of
eNOS and iNOS activity (32), giving further evidence that
reduced Ad in metabolic disorders disrupts endothelial
function, a pivotal event in the genesis and progression of
macroangiopathy (14), a significant cause of mortality in pa-
tients with metabolic syndrome and type-2 diabetes (12).
Many of Ad’s anti-inflammatory effects have been associ-
ated with eNOS activation, increasing endothelial bioavail-
able nitric oxide (NO) (10, 22), via Ad-invoked binding of
regulatory heat shock protein 90 to eNOS (68) (Fig. 5). Phar-
macologic blockade of eNOSwith NO-nitro-l-arginine methyl
ester attenuates Ad-inhibition of in vivo TNF-inflamed mi-
crovasculature leukocyte adhesion (46).
AMPK mediates Ad’s vascular effects in endothelial cells
involving eNOS activation, as AMPK activation by Ad in-
creases endothelial NO availability, as well as signaling
through phosphatidylinositol 3¢-kinase (10). The influence of
Ad upon angiogenesis is dependent upon Ad-induced phos-
phorylation of both AMPK and Akt (protein kinase B), with
AMPK upstream of Akt, as disruption of AMPK activation
inhibits Ad-induced Akt phosphorylation (44).
Ad also affects endothelium via pathways involving pro-
tein kinase A (PKA, or cyclic AMP [cAMP]-dependent protein
kinase) signaling (43, 69). Ouchi and colleagues demonstrated
the accumulation of cAMP within endothelial cells, whereas
gAd suppressed TNF-induced NFkB activation and phos-
phorylated IkBa (an NFkB inhibitor); such action was blocked
by inhibitors of adenylate cyclase or PKA (43). Oligomers of
recombinant gAd and fAd have been shown to suppress
high-glucose-induced reactive oxygen species production, as
well as increase cellular cAMP content, and blocking PKA
inhibition in endothelial cells (47).
In addition to suppressing TNF-induced or high-glucose-
induced NFkB activation, gAd also potently blocks up-
stream enzyme Ikb kinase action (67). Whereas forskolin (an
adenylate cyclase activator) mimics the action of gAd, di-
deoxyadenosine (an adenylate cyclase inhibitor) as well as
Rp-cAMP (a PKA inhibitor) block gAd inhibition of TNF-
induced Ikb kinase activity (67). Altogether, these findings
suggest the great complexity of multiple pathways involved
in Ad-mediated suppression of endothelial inflammatory
signaling (summarized in Fig. 5).
Ad and cardiac injury
Numerous epidemiological studies have revealed the cor-
relation of reduced Ad levels with increased cardiovascular
disease risk (18, 23, 30, 74), and the relationship persists even
after adjustment for diabetes, dyslipidemia, hypertension,
smoking, and BMI (28, 30). High plasma Ad concentrations
are associated with a lower risk of MI in men (17, 30, 49).
Ethnic disparities in Ad levels might explain predilection in
African Americans and those of South Asian descent for in-
creased type-2 diabetes and coronary artery disease (13, 26,
51). Persistently, low plasma Ad concentration after acute
myocardial infarction is predictive of future adverse cardiac
events (3). In addition, recent clinical observations have
demonstrated that post-MI plasma Ad levels correlated pos-
itively with myocardial salvage index and ejection fraction
recovery (54). As such, reduced Ad production has been rec-
ognized as a risk factor of cardiovascular disease.
Experimental studies have generated more direct evidence
supporting the link between hypoadiponectinemia and car-
diomyocyte injury. In vitro studies have demonstrated that Ad
promotes cell survival and inhibits cell death, suggesting that
Ad may have direct cardioprotective effects atop its vasculo-
protective properties, which indirectly shield cardiomyocytes
from ischemia/reperfusion injury. Indeed, we and others
have recently demonstrated that, in addition tomicrovascular
defects, Ad knock-out (AdKO) mice manifest worse MI/R
injury compared to control mice, in measures such as in-
creased myocardial apoptosis and infarct size, and decrease
cardiac function (56, 62). Compared to controls, there is in-
creased MI/R injury in heterozygous Ad knock-out mice
( +/- ), in which circulating Ad levels are reduced by ap-
proximately half, but the severity was significantly less than
that seen in homozygous knock-out animals (62). This finding
suggests that Ad levels not only inversely correlate with the
risk of development of ischemic heart disease (as indicated by
the human epidemiological data), but also are inversely re-
lated to the severity of an MI/R insult. Provision of fAd or
gAd in dose-dependent manner ameliorates exacerbated MI/
R injury in AdKOmice (56, 62). These exciting results suggest
that Ad might eventually be utilized as a novel therapeutic
agent in the treatment of ischemic cardiac injury.
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As stated earlier, Ad is known to stimulate NO production
via AMPK-mediated eNOS phosphorylation. Lack of Ad,
therefore, might conceivably reduce NO production, thus
rendering cardiomyocytes more susceptible to MI/R injury.
However, this hypothesis is not supported by experimental
findings revealingmarkedly increased, rather than decreased,
total NO production in ischemic–reperfused tissue obtained
from AdKO mice [Tao et al. (62)]. Interestingly, iNOS ex-
pression is increased in AdKOmice compared to controls, and
gAd treatment effectively blocks iNOS expression in the
AdKO animals (62). These novel results indicate that Ad dif-
ferentially regulates NO production by both eNOS and iNOS.
Under physiologic conditions, Ad stimulates NO production
via eNOS phosphorylation, and thus contributes to its vaso-
dilatory, anti-inflammatory, and vascular-protective actions
through an AMPK-dependent pathway. In contrast, under
pathologic conditions when iNOS is induced, Ad prevents
excess NO generation by inhibiting iNOS expression and this
antinitrative action of Ad is largely AMPK independent (64,
66) (Fig. 6).
Ad Resistance as a New Risk Factor
of Cardiovascular Disease
Ad metabolically mimics insulin, promoting glucose up-
take and inhibiting hepatic glucose production (4). Ad exerts
anti-inflammatory and antiatherogenic properties via its vas-
cular stimulation of endothelial NO production (10). In-
creasing studies have demonstrated the association between
resistance to Ad’s metabolic/vascular effects with insulin re-
sistance and endothelial dysfunction in cardiovascular dis-
eases (23, 45). We review the phenomenon of Ad resistance as
a novel risk factor for cardiovascular disease and pathology.
High fat (HF)-rich diets impair the insulin-signaling cas-
cade by incremental skeletal muscle lipid accumulation (31).
As mechanistically described above, a primary physiologic
effect of Ad is increased fatty acid (FA) oxidation. Animals
subjected to HF-diet manifest Ad resistance, demonstrating
blunted FA oxidation in response to Ad administration, in
addition to decreased maximal insulin-stimulated glucose
transport (38). Mullen’s later studies investigating HF-fed rats
revealed temporal relevance and importance to Ad resistance;
the loss of Ad’s stimulatory effect on FA oxidation preceded
the increase in plasmalemmal fatty acid transporters.
Through resultant accumulation of intramuscular diacylgly-
cerol (DAG) and ceramide, insulin signaling was conse-
quently blunted, and maximal insulin-stimulated glucose
transport in skeletal muscle impairment occurred after the
onset of Ad resistance (37). In studying obese patients mani-
festing no significant insulin resistance, Bruce and colleagues
discovered that their subjects had deficient serum Ad levels.
Further, blunted AMPK activation in response to exogenous
gAd in obese muscle further suggested Ad resistance devel-
opment in obesity (8). Taken together, Ad system derange-
ment likely plays a central role in obesity or HF-diet-induced
insulin resistance.
We have conducted a series of studies investigating Ad
resistance in the vasculature. Utilizing a rat model with HF-
diet-induced obesity, we determined whether obesity/
hyperlipidemia alters the vascular response to Ad (33). We no-
ted a significant peaked plasma Ad level in HF-diet-fed animals
by 8 weeks, which rapidly declined thereafter. Regardless of
circulatory Ad levels, phosphorylated AMPK and eNOS in
vascular tissue remained significantly reduced at all observed
time points. Recombinant full-length Ad (rAd)-induced
AMPK/eNOS phosphorylation and vasodilatation were sig-
nificantly reduced in 16-week obese/hyperlipidemic aortic
segments. Vascular AdipoR1 and AdipoR2 expression levels
were significantly reduced after 16weeks of HF diet. Our data
supported that modification/inactivation of Ad by unidenti-
FIG. 6. Ad signaling in cardio-
myocytes. Ad isoforms have been
shown to exert multiple actions,
such as activation of AMP kinases,
CRT/CD91 activation with COX-2
involvement, suppression of TNF
signaling via a COX-2-prostaglan-
din E2-linked cascade (26a), and
reduction of oxidative and nitrative
stress after MI/R injury that is as-
sociated with suppression of iNOS
induction. CD91, CRT adapter
protein; MI/R, myocardial ische-
mia-reperfusion. (To see this illus-
tration in color the reader is
referred to the web version of this
article at www.liebertonline.com/
ars).
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fied factors present in obese/hyperlipidemic plasma de-
creased vascular AdipoR1/R2 expression, and reduced cir-
culating Ad levels all contribute to vascular Ad resistance at
varying stages of obesity.
In a yet unpublished study, we examined the reduced
cardioprotective action of Ad in a HF-diet-induced diabetic
mouse model, and its involved mechanisms. As many studies
in normal animals have demonstrated, Ad (Ad) reducesMI/R
injury. However, our preliminary experiments revealed the
attenuation of Ad-mediated cardioprotection in the diabetic
state, where there existed already significantly reduced en-
dogenous Ad levels. HF-diet-induced obesity/diabetic mice
and age-matched control mice on normal diet (ND) were
subjected to myocardial ischemia/reperfusion, and were
treated with gAd before reperfusion. In comparison to ND
mice, HF-diet mice endured greater MI/R injury. A nearly
threefold greater gAd dosewas required to achieve significant
cardioprotection comparable to that observed in ND mice
treated with standard Ad dose. Compared to ND mice, gAd-
induced cardiac AMPK activation was significantly blunted in
HF mice. Moreover, although both low and high doses of gAd
were equally effective in attenuating MI/R-induced oxidative
stress (NADPH oxidase expression and superoxide produc-
tion) and nitrative stress (iNOS expression, NO production,
and peroxynitrite formation) in ND mice, only high-dose gAd
effectively reducedMI/R-induced oxidative/nitrative stress in
HF mice. Taken together, our results demonstrated that HF-
induced diabetes diminished both AMPK-dependent and
AMPK-independent cardioprotection of gAd, suggestive of an
unreported Ad resistance in the diabetic heart.
Summary and Perspective
Ad, an endogenous insulin-sensitizing hormone, is an
abundantly produced adipocytokine of primarily adipose
origin, and circulates in plasma as various multimeric com-
plexes. Deficiency and/or imbalance of Ad’s oligomeric forms
has well-described associations with insulin resistance, ath-
erosclerosis, endothelial dysfunction, and cardiovascular
disease. Fourmajor biologic functions have been identified for
Ad: (i) metabolic regulatory function, (ii) vascular protective
function, (iii) anti-inflammatory role, and (iv) cardioprotec-
tive/anti-ischemic properties. The major intracellular path-
way activated by Ad includes phosphorylation of AMP-
activated protein kinase, which is responsible for many of
Ad’s properties. Additionally, several AMPK-independent
mechanisms for Ad’s anti-inflammatory and cardioprotective
actions have been delineated.
Pharmacologic agents (i) augmenting Ad’s circulating
concentrations (including novel or existing medications), (ii)
increasing Ad receptor expression, or (iii) dispersing specific
Ad receptor agonists capable of downstream signaling path-
way induction are all potential therapeutic modalities for
ameliorating disease pathologies discussed in this review.
Ad’s roles in disease processes via elucidated and yet un-
known mechanisms provide the potential for multiple thera-
peutic targets with clinical applications. Increasing attention
to Ad in recent years is well warranted given the potential
salutary benefits of the protein in numerous studies. Further
work will reveal the definitive effects and contributions of the
multiple Ad oligomeric forms in the vasculature, cardiac, and
metabolic systems.
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Abbreviations Used
ACC¼ acetyl co-A carboxylase
Ad¼ adiponectin
AdipoR1¼ adiponectin receptor 1
AdipoR2¼ adiponectin receptor 2
AdKO¼ adiponectin knock out
AMPK¼AMP-activated protein kinase
APPL1¼ adapter protein
CAMs¼ cell adhesion molecules
CD91¼CRT adapter protein
COX-2¼ cyclo-oxygenase 2
CPT1¼ carnitine palmotyltransferase 1
CRT¼ calreticulin
eNOS¼ endothelial nitric oxide synthase
fAd¼ full-length adiponectin
G6Pase¼ glucose-6-phosphatase
gAd¼ globular domain of adiponectin
HMW¼high molecular weight
Hsp90¼heat shock protein 90
IKKb¼ Ikb kinase
iNOS¼ inducible nitric oxide synthase







ROS¼ reactive oxygen species
TNFa¼ tumor necrosis factor alpha
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